ERBB2 and colorectal carcinoma: Considering that dual blockade of EGFR and ERBB2 was previously found to increase efficacy in CRC patients [23], we tested the combined action on CAR1 cells of pevonedistat with either cetuximab or the dual EGFR/ERBB2 kinase inhibitor lapatinib.